Last viewed:
PLRX
Prices are updated after-hours
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
(0.0% 1d)
(-9.2% 1m)
(-54.3% 1y)
(0.0% 2d)
(-2.1% 3d)
(-8.4% 7d)
(59.68%
volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 774,675,803
http://www.pliantrx.com
Sec
Filling
|
Patents
| 62 employees
(US) Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
add to watch list
Paper trade
email alert is off
Press-releases
Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight
Published: 2024-04-03
(Crawled : 22:00)
- prnewswire.com
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
| -8.11%
| O: 1.87%
H: 3.4%
C: -1.02%
fibrosis
therapeutics
growth
market
Pliant Therapeutics to Participate in Upcoming Investor Events
Published: 2024-04-02
(Crawled : 12:00)
- globenewswire.com
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
| -9.18%
| O: -0.62%
H: 1.17%
C: 1.17%
therapeutics
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
Published: 2024-03-27
(Crawled : 14:30)
- globenewswire.com
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
| -6.22%
| O: 1.34%
H: 3.63%
C: 1.54%
conference
international
therapeutics
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2024-03-12
(Crawled : 12:00)
- globenewswire.com
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
| -8.74%
| O: 0.0%
H: 6.88%
C: 4.2%
treatment
fibrosis
bexotegrast
therapeutics
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
Published: 2024-03-12
(Crawled : 17:00)
- biospace.com/
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
| -8.74%
| O: 0.0%
H: 6.88%
C: 4.2%
MRKR
|
$4.4
0.23%
11K
|
Consumer Services
| 6.28%
| O: -1.2%
H: 4.88%
C: 3.17%
therapeutics
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Published: 2024-02-27
(Crawled : 21:00)
- globenewswire.com
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
| -22.95%
| O: 4.59%
H: 0.0%
C: -7.67%
update
therapeutics
financial
results
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2024-02-26
(Crawled : 13:00)
- globenewswire.com
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
| -19.29%
| O: -0.3%
H: 4.27%
C: 1.4%
therapeutics
Pliant Therapeutics to Participate in Upcoming Investor Events - February 7, 2024
Published: 2024-02-07
(Crawled : 15:00)
- biospace.com/
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
| -17.69%
| O: 0.0%
H: 0.93%
C: -0.87%
therapeutics
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2024-02-04
(Crawled : 00:00)
- globenewswire.com
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
| -23.79%
| O: -3.62%
H: 0.0%
C: -5.78%
liver
positive
fibrosis
bexotegrast
trial
therapeutics
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03
(Crawled : 13:00)
- globenewswire.com
PLRX
|
$12.86
-3.02%
-3.11%
270K
|
Health Technology
| -26.17%
| O: 0.28%
H: 3.44%
C: 0.28%
conference
therapeutics
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount